Call for Abstracts - Late Breaking Science

Abstract submission deadline: 15 April 2024

במסגרת הכינוס יתקיים מושב מליאה חדש ביום שני 3 ביוני 2024 אחה”צ בנושא Late Breaking Science. מטרת המושב לתת במה למחקר קליני איכותי בקרדיולוגיה שבוצע לאחרונה בישראל ופורסם או התקבל לפירסום בעיתונות הקרדיו7לוגית המובילה.

תנאי הגשה:
1 – מחקר קליני שהתקבל לפירסום או התפרסם בעיתון בדירוג Q1 החל מיולי 2023.
2 – עבודה שבוצעה בארץ או שהמרכז שהוביל את המחקר הוא בישראל

Abstract Regulations

With the submission of an abstract, the first author (presenting author):

Accepts responsibility for the accuracy of the submitted abstract.
Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
Gives permission for the abstract, when selected for presentation (oral or poster), to be published.
Encore abstracts will be accepted.
Submitted abstracts cannot withdrawn after the official submission deadline.

Abstract Format

In order to be considered, an abstract should respect the following guidelines:

The abstract must be submitted in good English.
The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.
Abstract titles should be brief and should reflect the content of the abstract.
Commercial names may not be used in the abstract title.
No more than 10 authors can be listed. Only institutional affiliations, cities and countries should follow.

Abstracts on “trials in progress” can be submitted and will be considered for oral or poster presentation as long as they contain at least some preliminary and presentable results.

The decision regarding inclusion in the program and type of presentation will be decided by the Scientific Program Committee.

Abstracts should be organized under the headings:

Introduction -> Material and method -> Results and discussion -> Conclusion

The online abstract submission procedure will not accept abstracts that exceed 300 words (body of the abstract).

Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.

Supplementary data or appendices will not be accepted.

Figures or photographs are allowed. Symbols and structures of drugs are allowed and should be drawn in black.

Only the submitting author will receive a confirmation/abstract number by e-mail from the IHS2024 Secretariat within 48 hours of submission. This confirmation of abstract receipt is NOT a notice of acceptance.

For questions regarding the online submission process please contact the Conference secretariat.

Abstract Selection Process

Only abstracts submitted online can be accepted. Abstracts submitted on paper or by e-mail attachment will not be considered.
The Scientific Committee will make the selection of abstracts for oral and poster presentations on May 2024.
If a selected author cannot attend, the presenting author should assign a replacement.
If you do not receive any confirmation within 48 hours, please contact the Conference Secretariat within one week following the submission of the abstract.
Submitting an abstract for IHS2024 does not constitute registration for the meeting. All abstract submitters must complete their registration and payment to the IHS2024 meeting by May 20, in order to be considered as part of the scientific program.

HEB

Call for Abstracts - Late Breaking Science

Abstract submission deadline: 15 April 2024

Abstract Regulations

With the submission of an abstract, the first author (presenting author):

Accepts responsibility for the accuracy of the submitted abstract.

Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.

Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.

States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.

Gives permission for the abstract, when selected for presentation (oral or poster), to be published.

Encore abstracts will be accepted.

Submitted abstracts cannot withdrawn after the official submission deadline.

Abstract Format

In order to be considered, an abstract should respect the following guidelines:

The abstract must be submitted in good English.

The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.

Abstract titles should be brief and should reflect the content of the abstract.

Commercial names may not be used in the abstract title.

No more than 10 authors can be listed. Only institutional affiliations, cities and countries should follow.

Abstracts on “trials in progress” can be submitted and will be considered for oral or poster presentation as long as they contain at least some preliminary and presentable results.

The decision regarding inclusion in the program and type of presentation will be decided by the Scientific Program Committee.

Abstracts should be organized under the headings:

Introduction -> Material and method -> Results and discussion -> Conclusion

The online abstract submission procedure will not accept abstracts that exceed 300 words (body of the abstract).

Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.

Supplementary data or appendices will not be accepted.

Figures or photographs are allowed. Symbols and structures of drugs are allowed and should be drawn in black.

Only the submitting author will receive a confirmation/abstract number by e-mail from the IHS2024 Secretariat within 48 hours of submission. This confirmation of abstract receipt is NOT a notice of acceptance.

For questions regarding the online submission process please contact the Conference secretariat.

Abstract Selection Process

Only abstracts submitted online can be accepted. Abstracts submitted on paper or by e-mail attachment will not be considered.

The Scientific Committee will make the selection of abstracts for oral and poster presentations on May 2024.

If a selected author cannot attend, the presenting author should assign a replacement.

If you do not receive any confirmation within 48 hours, please contact the Conference Secretariat within one week following the submission of the abstract.

Submitting an abstract for IHS2024 does not constitute registration for the meeting. All abstract submitters must complete their registration and payment to the IHS2024 meeting by May 20, in order to be considered as part of the scientific program.

For questions regarding the online submission process, contact the Conference Secretariat.

KEEP ME UPDATED